Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 1—January 2019
CME ACTIVITY - Research

Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004–2010

Alexander C. EwingComments to Author , Nicole L. Davis, Dumbani Kayira, Mina C. Hosseinipour, Charles van der Horst, Denise J. Jamieson, Athena P. Kourtis, and for the BreastfeedingAntiretrovirals and Nutrition study team
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.C. Ewing, N.L. Davis, D.J. Jamieson, A.P. Kourtis); University of North Carolina Project, Lilongwe, Malawi (D. Kayira); University of North Carolina, Chapel Hill, North Carolina, USA (M.C. Hosseinipour, C. van der Horst)

Main Article

Table 2

Baseline characteristics of HIV-exposed, uninfected infants in the Breastfeeding, Antiretrovirals and Nutrition study, Malawi, 2004–2010*

Characteristic Total Before CPT After CPT p value†
No. infants
 2,152
 692 (32.16)
 1,460 (67.84)
Maternal education 1.0
None 245 (11.4) 81 (11.7) 164 (11.3)
Primary 1,153 (53.7) 369 (53.3) 784 (53.8)
Secondary 730 (34.0) 236 (34.1) 494 (33.9)
Tertiary
21 (1.0)
 6 (0.9)
 15 (1.0)
Maternal CD4, cells/μL‡ 440 (330–582) 437 (328–596.5) 441 (330–578) 0.8
Maternal HIV viral load during pregnancy, copies/mL‡ 16,045 (4,462–48,857) 17,231 (5,194.5–51,274) 15,281 (4,339–48,192) 0.2
Maternal age at delivery, y‡ 26 (22, 29) 25 (22–29) 26 (23–29) 0.047
Male infant 1,088 (50.6) 358 (51.7) 730 (50.0) 0.5
Infant birthweight, g‡
 3,000 (2,700–3,300)
 3,000 (2,700–3,300)
 3,000 (2,700–3,300)
 0.7
Treatment group 0.002
Control 597 (27.7) 227 (32.8) 370 (25.3)
Maternal ARV 766 (35.6) 229 (33.1) 537 (36.8)
Infant nevirapine 789 (36.7) 236 (34.1) 553 (37.9)
Nutrition group 1,076 (50.0) 345 (49.9) 731 (50.1) 0.9

*Data from 6 wks after birth overall and according to baseline visit timing relative to cotrimoxazole prophylaxis guideline implementation in June, 2006. Values are no. (%) unless otherwise indicated. ARV, antiretroviral therapy; CPT, cotrimoxazole preventive therapy.
†P values for continuous variables based on Kruskal-Wallis test.; p values for categorical variables based on the Pearson χ2 test.
‡Median (interquartile range).

Main Article

1Team members are listed at the end of this article.

Page created: December 12, 2018
Page updated: December 12, 2018
Page reviewed: December 12, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external